NAUT Nautilus Biotechnology, Inc.

NASDAQ
$1.57

Nautilus Biotechnology, Inc. (NAUT) is expected to report earnings on November 2, 2026, before the market open. The consensus earnings estimate is a loss of $0.14 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.9% since its last earnings release on July 28, 2026.

Nautilus Biotechnology, Inc. Reported Earnings
Tuesday, July 28, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 2
Monday · 8:00 AM ET
Earnings Whisper
-
vs ($0.14)
Rev est $200K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.20

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Nautilus Biotechnology, Inc.

Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.